Sangamo Therapeutics, Inc. (SGMO) Financials
SGMO Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 165.3 million | 82.4 million |
2023-09-30 | 219.7 million | 84.8 million |
2023-06-30 | 325.1 million | 91.4 million |
2023-03-31 | 440.6 million | 105.0 million |
SGMO Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -53.2 million | 6.1 million |
2023-09-30 | -50.0 million | 6.2 million |
2023-06-30 | -66.3 million | 6.8 million |
2023-03-31 | -76.5 million | 8.3 million |
SGMO Net Income
No data available :(
SGMO Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 81.0 million | - | 38.1 million |
2023-09-30 | 132.1 million | - | 35.0 million |
2023-06-30 | 143.1 million | - | 36.4 million |
2023-03-31 | 205.4 million | - | 37.7 million |
SGMO Shares Outstanding
SGMO Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 2.7 million | 51.2 million | 13.1 million | -2.9 million |
2023-09-30 | 2.7 million | 57.1 million | 13.9 million | - |
2023-06-30 | 5.5 million | 63.0 million | 16.0 million | - |
2023-03-31 | 10.2 million | 63.2 million | 18.1 million | - |
SGMO Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 2.0 million | 3.0 million |
2023-09-30 | 9.4 million | 9.5 million |
2023-06-30 | 6.8 million | 4.3 million |
2023-03-31 | 158.0 million | 3.5 million |
SGMO
Price: $0.56
52 week price:
Earnings Per Share: -1.48 USD
P/E Ratio: -0.39
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 882100
Ebitda: -12.6 millionMarket Capitalization: 115.3 million